Condition
Diabetes Mellitus, Type 2
Locations
Argentina, Australia, Brazil, Germany, Greece, Hungary, India, Israel,
Poland, Romania, Spain, Taiwan, United States
Start date
05/11/2024
Identifiers
Trial ID
NN9388-7741,
NCT number NCT06534411,
Eudract number Not Available
NCT number NCT06534411,
Eudract number Not Available
Summary
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Trial Overview:
Treatment
DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Tirzepatide
Study type
INTERVENTIONAL
Trial duration
Nov 05 2024 - Aug 18 2026
Participants
1000
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.